[
  {
    "ts": null,
    "headline": "Sage Therapeutics Announces Second Quarter 2025 Financial Results",
    "summary": "CAMBRIDGE, Mass., July 30, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.",
    "url": "https://finnhub.io/api/news?id=14ab96260f18acd86f46697e21eb78ce601375caa41a872573419c23157d03ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753905900,
      "headline": "Sage Therapeutics Announces Second Quarter 2025 Financial Results",
      "id": 136149857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., July 30, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.",
      "url": "https://finnhub.io/api/news?id=14ab96260f18acd86f46697e21eb78ce601375caa41a872573419c23157d03ae"
    }
  },
  {
    "ts": null,
    "headline": "Alkermes: A More Than Solid Quarter",
    "summary": "Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress. Click to read why ALKS is a Hold.",
    "url": "https://finnhub.io/api/news?id=ca853c2f00b51b120fb7f12e7919f60abd9141b07c084d2d2a03ce81388630f2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753895335,
      "headline": "Alkermes: A More Than Solid Quarter",
      "id": 136146186,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress. Click to read why ALKS is a Hold.",
      "url": "https://finnhub.io/api/news?id=ca853c2f00b51b120fb7f12e7919f60abd9141b07c084d2d2a03ce81388630f2"
    }
  },
  {
    "ts": null,
    "headline": "Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the two-year real-world study in the U.S. of lecanemab (generic name, product name: LEQEMBI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – t",
    "url": "https://finnhub.io/api/news?id=b3906b42bde383ad4b8873d5f06794dbf3dbdc54edacba5b3a54c8373d1acc8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753887600,
      "headline": "Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025",
      "id": 136149858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the two-year real-world study in the U.S. of lecanemab (generic name, product name: LEQEMBI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – t",
      "url": "https://finnhub.io/api/news?id=b3906b42bde383ad4b8873d5f06794dbf3dbdc54edacba5b3a54c8373d1acc8f"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=fc786c739f1a245a5629067131f52d1297f511d6e36f6cac2658a531d853a9a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753881302,
      "headline": "Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures",
      "id": 136149859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=fc786c739f1a245a5629067131f52d1297f511d6e36f6cac2658a531d853a9a1"
    }
  },
  {
    "ts": null,
    "headline": "New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SC-AI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Confere",
    "url": "https://finnhub.io/api/news?id=cc61adf01df02de7623c2e0bfba4953297c5591ff2ff11c4185f87dca8b1d807",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753880400,
      "headline": "New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease",
      "id": 136130795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SC-AI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Confere",
      "url": "https://finnhub.io/api/news?id=cc61adf01df02de7623c2e0bfba4953297c5591ff2ff11c4185f87dca8b1d807"
    }
  },
  {
    "ts": null,
    "headline": "Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 20",
    "url": "https://finnhub.io/api/news?id=cb0b602093679f8a86cc18df99bb38d99b94f162671f2f79ef7a97c6bcc66129",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753877220,
      "headline": "Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC",
      "id": 136130796,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 20",
      "url": "https://finnhub.io/api/news?id=cb0b602093679f8a86cc18df99bb38d99b94f162671f2f79ef7a97c6bcc66129"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
    "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
    "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753868462,
      "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
      "id": 136129640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
      "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Earnings: What To Look For From BIIB",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know.",
    "url": "https://finnhub.io/api/news?id=2fe3b083c252de9b526ead7cadb297e31fd0b1a382c5e550e4c760f9d1eb5552",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753844813,
      "headline": "Biogen Earnings: What To Look For From BIIB",
      "id": 136130798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know.",
      "url": "https://finnhub.io/api/news?id=2fe3b083c252de9b526ead7cadb297e31fd0b1a382c5e550e4c760f9d1eb5552"
    }
  }
]